

Data Sharing Statement

| | | |
|---------------------|--|---|
| Article Info | https://dx.doi.org/10.21037/tbcr-21-42 | |
| Item | Question | Authors' Response (place "-" if not applicable) |
| 1 | Would you like to share data collected for your study to others? | Yes |
| 2 | If not, would you like to share the reason for your decision? | - |
| 3 | What data in particular will be shared? | The progression-free survival data in particular will be shared, and we also found patients with liver metastases might have better PFS benefit from inetetamab plus vinorelbine treatment. |
| 4 | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Study protocol and informed consent form will also be shared if requested. |
| 5 | When will data availability begin? | From the publication date. |
| 6 | When will data availability end? | Two years within the publication date, since the technique or survival date may be updated over time. |
| 7 | To whom will you share the data? | Breast cancer expert who are interested in studies of inetetamab. |
| 8 | For what type of analysis or purpose? | For analysis to evaluate the efficacy and safety safety of inetetamab in breast cancer patients. |
| 9 | How or where can the data/documents be obtained? | Emails could be sent to the address below to obtain the shared data: Lyn9500@163.com |
| 10 | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |